Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Phase 1 showed the drug was real
Tirzepatide produced a mean weight reduction of 20.2% compared to 13.7% with semaglutide a statistically significant 6.5 percentage point difference
The rates are broadly similar
doi: 10.1210/clinem/dgaa863 Summary Keywords obesity, insulin-resistance, Tirzepatide, pathophysiology, GIP, GLP - 1, clinical trials, arterial hypertension Citation Corrao S, Pollicino C, Maggio D, Torres A and Argano C (2024) Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
US$ 25.04
US$ 25.35
US$ 26.25
US$ 25.99
